1. Home
  2. ITRG vs STTK Comparison

ITRG vs STTK Comparison

Compare ITRG & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Integra Resources Corp.

ITRG

Integra Resources Corp.

HOLD

Current Price

$2.14

Market Cap

529.9M

ML Signal

HOLD

Logo Shattuck Labs Inc.

STTK

Shattuck Labs Inc.

HOLD

Current Price

$7.04

Market Cap

538.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ITRG
STTK
Founded
1997
2016
Country
Canada
United States
Employees
N/A
N/A
Industry
Precious Metals
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
529.9M
538.3M
IPO Year
2017
2020

Fundamental Metrics

Financial Performance
Metric
ITRG
STTK
Price
$2.14
$7.04
Analyst Decision
Strong Buy
Buy
Analyst Count
2
7
Target Price
$5.13
$10.00
AVG Volume (30 Days)
3.0M
1.5M
Earning Date
05-11-2026
05-01-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
53.02
EPS
N/A
N/A
Revenue
N/A
$1,000,000.00
Revenue This Year
$67.34
N/A
Revenue Next Year
$25.89
N/A
P/E Ratio
$45.07
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.43
$0.71
52 Week High
$4.87
$8.33

Technical Indicators

Market Signals
Indicator
ITRG
STTK
Relative Strength Index (RSI) 41.71 59.92
Support Level $2.01 $5.87
Resistance Level $2.98 $7.69
Average True Range (ATR) 0.10 0.62
MACD 0.01 0.02
Stochastic Oscillator 43.08 77.96

Price Performance

Historical Comparison
ITRG
STTK

About ITRG Integra Resources Corp.

Integra Resources Corp is a precious metals exploration and development company in the Great Basin of the Western USA. Integra is currently focused on advancing its two flagship oxide heap leach projects: the past-producing DeLamar Project located in southwestern Idaho and the Nevada North Project, comprised of the Wildcat and Mountain View deposits, located in northwestern Nevada. The company also holds a portfolio of prospective early-stage exploration projects in Idaho, Nevada, and Arizona.

About STTK Shattuck Labs Inc.

Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.

Share on Social Networks: